A phase I first in human, randomized, double blind, placebo-controlled study evaluating the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of escalating single and multiple doses of P014
Latest Information Update: 04 Feb 2021
At a glance
- Drugs P-014 (Primary)
- Indications Autoimmune disorders; Inflammation
- Focus Adverse reactions; First in man; Pharmacodynamics; Pharmacokinetics
- Sponsors Kira Pharmaceuticals
- 04 Feb 2021 New trial record
- 02 Feb 2021 According to the Kira Pharmaceuticals Media Release, first healthy volunteer has been successfully dosed in this trial.